Trial Profile
Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease (TRAIL1)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Interstitial lung diseases; Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TRAIL1
- 13 Aug 2021 Status changed from recruiting to completed.
- 19 May 2021 Results (n=123) evaluating the Baseline Characteristics of Participants in the Treatment for Rheumatoid Arthritis and Interstitial Lung Disease 1 (TRAIL1) Trial presented at the 117th International Conference of the American Thoracic Society
- 12 Sep 2019 Trial design published in the Advances in Therapy